Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma.

McNeish, I A; Monk, B J

McNeish, I A; Monk, B J.

Affiliation

McNeish IA; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK. Electronic address: i.mcneish@imperial.ac.uk.
Monk BJ; HonorHealth Research Institute, Division of Gynecologic Oncology, University of Arizona College of Medicine, Phoenix, USA.

Ann Oncol ; 34(12): 1074-1076, 2023 12.

Article in En | MEDLINE | ID: mdl-38072509

Subject(s)

Antineoplastic Agents; Carcinoma; Ovarian Neoplasms; Female; Humans; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use; Ovarian Neoplasms/drug therapy; Ovarian Neoplasms/pathology; Carcinoma, Ovarian Epithelial; Antineoplastic Agents/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma / Antineoplastic Agents Limits: Female / Humans Language: En Journal: Ann Oncol Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google